J&J's New Growth Powerhouses: Immunology and Neuroscience
J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.
Zacks Investment Research8/18/2026Positive
JNJ
Johnson & JohnsonNYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$632.29B
P/E Ratio
30.23
EPS
$8.68
Beta
0.23
52W High
$274.90
52W Low
$170.33
50-Day MA
$251.31
200-Day MA
$229.78
Dividend Yield
2.01%
Profit Margin
21.50%
Forward P/E
22.37
PEG Ratio
4.56
About Johnson & Johnson
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Fundamentals
| Revenue (TTM) | $97.93B |
| Gross Profit (TTM) | $66.73B |
| EBITDA | $34.87B |
| Operating Margin | 29.20% |
| Return on Equity | 25.70% |
| Return on Assets | 8.60% |
| Revenue/Share (TTM) | $40.67 |
| Book Value | $35.28 |
| Price-to-Book | 7.38 |
| Price-to-Sales (TTM) | 6.46 |
| EV/Revenue | 6.7 |
| EV/EBITDA | 19.31 |
| Quarterly Earnings Growth (YoY) | -0.90% |
| Quarterly Revenue Growth (YoY) | 6.60% |
| Shares Outstanding | $2.41B |
| Float | $2.41B |
| % Insiders | 0.05% |
| % Institutions | 77.24% |
Historical Volatility
HV 10-Day
18.21%
HV 20-Day
22.07%
HV 30-Day
23.09%
HV 60-Day
25.50%
HV Rank
86.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($272.50 target)
5
Strong Buy11
Buy6
Hold1
SellLatest News
5 Dependable Dividend Stocks to Buy in August
Boring wins in August. While the market chases AI multiples and momentum trades, a quiet cohort of blue-chip dividend compounders continues doing what it has done for decades: raise the payout, return capital, and reward patience.
24/7 Wall Street8/18/2026Positive
Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research8/14/2026Positive
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
Zacks Investment Research8/14/2026Positive
5 Dividend Kings to Buy and Hold Forever in August
Dividend Kings, companies with at least 50 consecutive years of dividend increases, remain the backbone of any buy-and-hold income portfolio.
24/7 Wall Street8/14/2026Positive
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both delivered strong quarters, but they tell very different dividend stories.
24/7 Wall Street8/12/2026Positive
The Energy and Pharma Giants Quietly Funding HDV's 3% Yield, and How Safe Each One Is
The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout.
24/7 Wall Street8/12/2026Positive
Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?
At $261.81, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a hold.
24/7 Wall Street8/11/2026Neutral
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.
Zacks Investment Research8/11/2026Neutral
3 Beaten-Down Healthcare Stocks to Buy in August
Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.
24/7 Wall Street8/10/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on JNJ and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/19/2026